Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.07 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Lexicon Pharmaceuticals, Inc.'s return on equity, or ROE, is -103.16% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that LXRX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LXRX 1.07 0.00(0.00%)
Will LXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Other News for LXRX
Lexicon (LXRX) Regains Compliance with Nasdaq's Minimum Bid Rule
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement | LXRX ...
Lexicon regains compliance with Nasdaq minimum bid price requirement
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 | ...
Largest borrow rate increases among liquid names